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Abstract: Culture medium or medium supplement is one of the factors responsible for dendritic cell (DC) generation, but little
is known about the influence of various media on DC culture. In our study we generated DC from adherent monocytes of
human peripheral blood in the presence of GM-CSF, IL-4 and TNF-α . The following culture media were used: RPMI 1640
supplemented with 2% human serum albumin; RPMI 1640 supplemented with 2% TCH serum replacement; X-VIVO 15 and
Panserin 501. Flow cytometry analysis revealed that in all media cells were CD83+ and lost CD14. Interestingly, the use of
Panserin and RPMI with albumin preferentially gave rise to CD1a+ DC, whereas in X-VIVO and RPMI with TCH we observed
both CD1a+ and CD1a-. Our results showed that RPMI with TCH yielded the highest percentage of cells expressing both
CD80 and CD86 molecules and, in contrast to other media, the higher percentage of CD86+ cells in comparison to CD80+
cells.
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Introduction
Dendritic cells (DC) are the most potent antigen presenting
cells that play a pivotal role in the immune response by
processing and presenting antigens to T-cells [2, 9]. Fol-
lowing the discovery of methods to generate large numbers
of DC ex vivo, the use of DC as effective adjuvants for
cancer treatment was demonstrated in clinical studies [8,
13, 15]. The interest of recent investigations is focused
on the development of DC-based immunotherapy of
human malignant diseases [22, 28]. So, there is a demand
to establish reproducible and efficient methods to gener-
ate adequate number of fully functional DC for clinical
applications. For the first time, human DC were cultured
from CD34+ haematopoietic progenitors in the presence
of granulocyte-macrophage colony stimulating factor
(GM-CSF) and tumor necrosis factor alpha (TNF-α ) [5].
Then it was reported that DC can also be generated from
nonproliferating CD14+ monocytes of human periphe-
ral blood by cultivation with GM-CSF, IL-4 and matur-
ation stimuli such as monocyte-conditioned medium
(MCM), TNF-α , CD40L and PGE2 [3, 17-19, 20, 26, 27,
29]. Some studies demonstrated DC culturing from cord
blood CD34+ cells and monocytes [12, 30]. 
The method of DC generation from peripheral blood
monocytes is widespread in experimental and clinical
studies. It allows to obtain large numbers of monocyte-
derived DC without pretreatment of donors with any
cytokines to mobilize CD34+ stem cells from the bone
marrow into the peripheral blood [18]. The DC obtained
by this approach are mature and stable which is prefer-
able for the purpose of immunotherapy [18, 26]. More-
over, this method gives a possibility to generate DC
without involving xenologous proteins such as fetal calf
serum (FCS), which can be potentially infective and
immunogenic [3, 18]. Although the protocols for DC
culturing have been developed, they are still not stand-
ardized and need further improvements for clinical use.
It has been shown that generation of monocyte-derived
DC is not only dependent on certain cytokines [24], but
also on culture media and supplements [1, 7, 14, 16, 26].
However, little is known about the role of culture media
in DC cultivation. The aim of the present study was to
investigate the influence of different culture media on
generation of DC from peripheral blood mononuclear
cells (PBMC).
Materials and methods
Isolation of peripheral blood mononuclear cells (PBMC). Periph-
eral blood (50-100 ml) was obtained from 10 healthy volunteers by
venous puncture and collected in sterile heparinized tubes. The blood
was diluted 1:1 with phosphate buffered saline (PBS) without Ca2+
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2+ (used in all following experiments). PBMC were isolated
by centrifugation in density gradient (Gradisol L, Aqua Medica,
Poland) and washed twice in PBS before being resuspended in the
appropriate assay medium.
Generation of monocyte-derived DC. PBMC were plated in 6-well
tissue culture dishes (Greiner, Germany) at a density of 2 ×  106
cells/ml. Four culture media were used: RPMI 1640 (PAN Biotech
GmbH, Germany) supplemented with 2% human serum albumin
(Bioplasma AG, Switzerland), which we used in the standard proce-
dure; RPMI 1640 containing 2% TCH serum replacement (ICN
Biomedicals, USA); X-VIVO 15 serum-free medium (Biowittaker,
Walkersville, MD, USA); Panserin 501 with L-glutamine (PAN
Biotech GmbH, Germany). All media were supplemented with peni-
cillin (50 IU/ml), streptomycin (0.05 mg/ml) and neomycin (0.1
mg/ml) (Sigma, Germany). Mononuclear cells were incubated at
37˚C and 5% CO2 for 90 min for monocyte adherence. After the
incubation period, the non-adherent cells were removed by washing
twice with the respective medium; the cell culture dishes were filled
with cold PBS for 20 min at 4˚C and then finally washed with cold
PBS. The adherent cells were cultured in the respective medium
containing GM-CSF (1000 IU/ml, Leukomax Novartis, Switzerland)
and IL-4 (500 IU/ml, Strathmann Biotec AG, Germany). Cytokines
in the same dosages were added again on days 3 and 5; culture
medium was not changed. The maturation of DC was induced by
addition of TNF-α  (50 ng/ml, Strathmann Biotec AG, Germany) on
day 6. On day 8 cells were harvested and used for subsequent
experiments.
Cell staining. Immunofluorescent staining was performed according
to manufacturer’s protocols. Cells were stained with the following
directly conjugated monoclonal antibodies (MoAbs) in the following
combinations: mouse isotype control IgG1/IgG2A/IgG2A
FITC/PE/TC, CD45/CD14 FITC/PE, CD83/CD1a/HLA-DR
FITC/PE/CyChrome, CD80/CD86/HLA-DR FITC/PE/CyChrome
(HLA-DR from Pharmingen, USA; other MoAbs from Caltag, Bur-
Fig. 1. Gating of dendritic cells (R1) and residual lymphocytes (R2).
Fig. 2. Expression of surface markers: CD14 (a), CD83 (b), CD1a
(c), CD80 (d) and CD86 (e) on dendritic cells generated in different
culture media. X-axis shows fluorescence intensity, Y-axis - cell
number.
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2dlingame, CA, USA). In brief, after culturing cells were collected,
washed with PBS and incubated with MoAbs for 30 min at 4˚C. To
minimize FcR-mediated MoAb binding, cells were stained in the
presence of FcR-blocking reagent (Miltenyi Biotec, Germany).
Flow cytometry. Cells were analysed by three-color flow cytometry
technique using Becton Dickinson FACSCalibur, equipped with 488
nm argon laser. A minimum of 30 000 events were acquired and
analysed by CellQuest Software.
Statistical analysis. The nonparametric Wilcoxon matched pair
signed rank test was applied. Differences were considered as statis-
tically significant at p≤ 0.05.
Results
After culturing, all media gave comparable DC number
(79.44%±10.98 in RPMI with albumin, 70.74%±12.04
in RPMI with TCH, 77.56%±14.08 in X-VIVO,
72.74%±22.56 in Panserin), with a significant difference
between albumin- and TCH- containing media. The per-
centage of residual lymphocytes did not differ significantly
between these media (7.61%±5.21 in RPMI supplemented
with albumin, 10.19%±4.58 in RPMI with TCH,
11.49%±9.16 in X-VIVO 15 and 7.34%±5.17 in Panserin).
Analysis of surface markers expression of cultured
cells is shown in a representative experiment (Fig. 1).
The immunophenotypic characteristics of generated
cells is presented in Table 1.
We found that all media led to the loss of monocyte
surface marker CD14. There was also no significant
difference in the percentage of cells expressing CD83
molecule, a marker of mature DC. The percentage of
cells expressing CD1a, a marker of immature DC, was
the lowest in RPMI with TCH, and it significantly dif-
fered from X-VIVO and Panserin. 
We noticed a significant difference in the percentage
of cells with fully mature DC phenotype (83+1a-) be-
tween RPMI with albumin and RPMI with TCH as well
as between X-VIVO and Panserin. The percentage of
cells with partially mature DC phenotype (83+1a+)  was
the highest in Panserin and the lowest in TCH-contain-
ing RPMI, with a significant difference between these
media. Comparison of fully mature and partially mature
DC showed that their percentages did not differ signifi-
cantly in RPMI with TCH as well as in X-VIVO. The
percentage of 83+1a+ cells was significantly higher in
comparison to 83+1a- cells in albumin-containing me-
dium and Panserin.
Our findings showed that RPMI with TCH yielded the
highest percentage of cells expressing both CD80 and
CD86 costimulatory molecules, and it significantly dif-
fered from X-VIVO and Panserin. Comparison of CD80+
and CD86+ cells demonstrated that the percentage of
CD86+ cells was significantly higher than percentage of
CD80+ cells in RPMI with TCH, while there was no
significant difference between these cells in other media.
Discussion
Growth and maturation of DC in culture can be in-
fluenced by a variety of factors. One of them has been
shown to be culture medium or medium supplement.
Table 1. Immunophenotypes of cells cultured in different culture media
Cell surface 
immunophenotype (CD)
Percentages of cells in the studied culture media
RPMI 1640 with 
2% albumin
RPMI 1640 with 
2% TCH X-VIVO 15 Panserin 501
45+14- 87.64
77.45-95.34
80.65
71.89-86.18
84.58
67.76-94.37
83.44
79.60-94.39
83+ 37.29
26.95-47.56
55.41
16.28-68.45
48.10
35.53-66.07
61.31
45.11-64.47
1a+ 28.63
13.96-55.19
23.52
8.98-37.59
38.43
b
29.54-48.37
43.17
c
33.31-64.07
83+1a+ 22.34
11.20-32.70
17.96
8.55-34.88
28.22
20.33-37.47
40.37
c
31.33-57.47
83+1a- 7.04
a
2.12-14.86
13.70
8.19-40.15
15.78
d
3.85-37.38
9.06
5.36-30.96
80+ 70.40
44.09-83.94
80.05
60.34-91.58
56.21
b
33.88-72.11
59.99
c
44.28-61.16
86+ 73.63
a
45.51-83.75
87.12
78.37-93.67
55.88
b
37.61-71.94
58.67
c
44.03-77.56
80+86+ 67.73
42.97-82.23
79.50
59.42-90.97
49.75
b
33.58-71.86
57.23
c
43.58-60.93
Results are expressed as medians and 25th-75th percentiles of 10 experiments. Significant difference (p≤ 0.05) between: 
aRPMI with al-
bumin and RPMI with TCH, 
bX-VIVO 15 and RPMI with TCH, 
cPanserin and RPMI with TCH, 
dX-VIVO 15 and Panserin.
Human dendritic cells in culture 27The generation of DC was described in media sup-
plemented with FCS, human plasma or serum [1, 7, 16,
18]. For immunotheraupetic purposes it is desirable to
avoid FCS because its potential immunogenicity. Serum
or plasma contain growth factors or other substances,
which may influence the generation of DC, so it is
necessary to determine the appropriate concentration of
autologous plasma or serum in DC generation for each
patient. For serum-free cultures, X-VIVO, AIM-V and
RPMI 1640 were used [7, 14, 18, 26, 27], also human
albumin as protein component [1, 25]. However, the
literature on the effects of different media on monocyte-
derived DC generation is scarce. 
In our study we investigated the influence of RPMI
1640 supplemented with 2% albumin, RPMI 1640 sup-
plemented with 2% TCH, X-VIVO 15, and Panserin 501
on differentiation of DC from monocytes, with respect
to their phenotype. All these media are serum-free and
can be used for mammalian cell cultivation. The use of
medium supplemented with TCH and Panserin for DC
generation has not yet been described.
The number of cultured DC is one of important
characteristics of DC generation. Such medium supple-
ments as autologous plasma or serum, human serum and
fetal calf serum had no influence on DC yields [7, 14].
Also it has been shown that there is no difference be-
tween RPMI 1640 and X-VIVO media in DC yields [7,
26]. In our experiment, all media gave comparable DC
number. Nevertheless, the number of DC obtained in
RPMI 1640 with albumin was significantly higher than
in RPMI with TCH. Araki et al. observed that DC
number in culture with 2% albumin was consistently
higher than in cultures with autologous plasma or serum
[1].
The morphological appearance of DC generated in
X-VIVO was similar to that of cells cultured in RPMI
supplemented with albumin: during the culture cells
detached from plastic dishes and formed aggregates
consisting of dendritic-like cells. However, X-VIVO
contained smaller DC aggregates and occasional fibro-
blastic cells. In Panserin and RPMI with TCH we ob-
served less cells with dendritic morphology,
accompanied by fibroblast-like cells adherent to the
culture plates. TCH-containing medium was found to
have the strongest tendency to yield fibroblastic cells
(data not shown).
Our experiments showed that cells obtained in differ-
ent media displayed characteristic features of DC: they
lost CD14, monocyte surface marker, and expressed
CD83 molecule. CD83 is a typical marker of maturation
on human DC [18, 31]. 
CD1a is expressed on Langerhans cells but periphe-
ral blood DC never express it [9, 21]. It was also shown
that during culture with GM-CSF and IL-4, monocytes
differentiate into CD1a+ DC with further decreased
CD1a expression after maturation [18, 32] . We noticed
that DC cultured in X-VIVO 15 and RPMI with TCH
consisted of quantitatively almost equal populations of
CD1a+ and CD1a- cells, whereas RPMI supplemented
with albumin and Panserin preferentially led to the
generation of CD1a+ DC. In contrast to our data, some
studies demonstrated that X-VIVO resulted in rather
homogenous populations of mature DC, but these results
were controversial. Thurner et al. reported that the use
of X-VIVO 15 gave rise to CD1a- DC [26]. Other
authors observed CD1a-positive DC generated in X-
VIVO [7, 14, 30]. Interestingly, it was noticed that
culture media with such supplements as autologous plas-
ma or serum resulted in CD1a- and CD1a+ DC, whereas
DC obtained in serum-free media mostly had high up-
regulation of that marker [1, 7, 14, 16].
Our observation concerning albumin-supplemented
RPMI is in agreement with results of Araki et al. who
showed that monocytes differentiated into CD1a+ popu-
lation in 2% albumin-supplemented culture [1]. The
authors also noticed that DC obtained in albumin-con-
taining medium were effective in phagocytic activity,
similarly to DC generated in cultures with autologous
plasma or serum. Although CD1a molecule is con-
sidered to be a specific marker of immature DC [9, 21],
Thurner et al. found that fully mature DC generated in
RPMI 1640 still expressed CD1a molecules [26]. Simi-
larly, another investigation demonstrated that during DC
generation from peripheral and cord blood monocytes in
X-VIVO 15 medium even after addition of TNF-α ,
CD1a+ was further up-regulated in mature DC [30]. 
CD1a belongs to CD1 family of antigen presenting
molecules that are responsible for presenting lipid and
glycolipid antigens to T cells [4, 10, 23]. Thus, express-
ion of CD1a+ on DC may be significant in creating
non-peptide vaccines. 
CD80 and CD86 are characteristic of mature DC.
These costimulatory molecules initiate and stabilize DC
interaction with T-cells through the corresponding li-
gands [2, 9]. In our study, the number of cells expressing
both CD80 and CD86 was the highest in RPMI sup-
plemented with TCH. 
The expression of CD80 and CD86 molecules and
their role are likely dependent on DC precursors [6, 30].
The data on the influence of medium or culture supple-
ments on expression of CD80 or CD86 are controversial.
Vries et al. reported that DC generated from monocytes
of melanoma patients in AIM-V, X-VIVO 15 and RPMI
1640 media supplemented with human serum had com-
parable expression levels of costimulatory molecules
[27]. In contrast to these findings, Duperrier et al. found
that generation in human serum or autologous plasma
resulted in higher number of DC with up-regulated
CD86 expression in comparison with X-VIVO or FCS-
supplemented media [7]. Describing DC generation in
human plasma and FCS, Pietschmann et al. showed that
FCS-derived DC had higher CD80 expression, while in
28 N. Tkachenko et al.human plasma DC exhibited more mature profile and
higher expression of CD86 [16]. Interestingly, we ob-
served higher percentage of CD86-positive cells in
RPMI with TCH, while there was no difference between
cells expressing costimulatory molecules in other media.
Different expression of CD80 and CD86 molecules in
various culture media may be connected with the com-
pensation of each other in costimulatory functions,
which is supported by the fact that CD80 and CD86
provide similar costimulatory signals in T-cell response
[11], but further investigations are needed for under-
standing of such influences.
We believe that our findings demonstrate the signi-
ficance of culture medium role in DC generation from
peripheral blood monocytes and will facilitate to work
out a reproducible method that will be the most suitable
for experimental and clinical applications.
Acknowledgments: X-VIVO 15 medium was a generous gift from
Biokom, Poland, TCH was supported by ICN, Poland and Panserin
501 from Cytogen, Poland.
References
 [1]  Araki H, Katayama N, Mitani H, Suzuki H, Nishikawa H,
Masuya M, Ikuta Y, Hoshino N, Miyashita H, Nishii K, Minami
N, Shiku H (2001) Efficient ex vivo generation of dendritic cells
from CD14+ blood monocytes in the presence of human serum
albumin for use in clinical vaccine trials. Br J Haematol 114:
681-689
  [2] Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y,
Pulendran B, Palucka K (2000) Immunobiology of dendritic
cells. Annu Rev Immunol 18: 767-811
 [3] Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N
(1996) Improved methods for the generation of dendritic cells
from nonproliferating progenitors in human blood. J Immunol
Methods 196: 121-135
  [4] Cao X, Sugita M, Van Der Wel N, Lai J, Rogers RA, Peters PJ,
Brenner MB (2002) CD1 molecules efficiently present antigen
in immature dendritic cells and traffic independently of MHC
class II during dendritic cell maturation. J Immunol 169: 4770-
4777
 [5]  Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J
(1992) GM-CSF and TNF-alpha cooperate in the generation of
dendritic Langerhans cells. Nature 360: 258-261
  [6] Dilioglou S, Cruse JM, Lewis RE. Function of CD80 and CD86
on monocyte- and stem cell-derived dendritic cells (2003) Exp
Mol Pathol 75: 217-227
 [7] Duperrier K, Eljaafari A, Dezutter-Dambuyant C, Bardin C,
Jacquet C, Yoneda K, Schmitt D, Gebuhrer L, Rigal D (2000)
Distinct subsets of dendritic cells resembling dermal DCs can
be generated in vitro from monocytes, in the presence of differ-
ent serum supplements. J Immunol Methods 238: 119-131
  [8] Fong L, Brockstedt D, Benike C, Wu L, Engleman EG (2001)
Dendritic cells injected via different routes induce immunity in
cancer patients. J Immunol 166: 4254-4259
  [9] Hart DN (1997) Dendritic cells: unique leukocyte populations
which control the primary immune response. Blood 90: 3245-
3285
[10] Jullien D, Stenger S, Ernst WA, Modlin RL (1997) CD1 pres-
entation of microbial nonpeptide antigens to T cells. J Clin
Invest 99: 2071-2074
[11] Lanier LL, O’Fallon S, Somoza C, Phillips JH, Linsley PS,
Okumura K, Ito D, Azuma M (1995) CD80 (B7) and CD86
(B70) provide similar costimulatory signals for T cell prolifera-
tion, cytokine production, and generation of CTL. J Immunol
154: 97-105
[12] Liu A, Takahashi M, Narita M, Zheng Z, Kanazawa N, Abe T,
Nikkuni K, Furukawa T, Toba K, Fuse I, Aizawa Y (2002)
Generation of functional and mature dendritic cells from cord
and bone marrow CD34+ cells by two-step culture combined
calcium ionophore treatment. J Immunol Methods 261: 49-63
[13] Lodge PA, Jones LA, Bader RA, Murphy, GP, Salgaller ML
(2000) Dendritic cell-based immunotherapy of prostate cancer:
immune monitoring of a phase II clinical trial. Cancer Res 60:
829-833
[14] Loudovaris M, Hansen M, Suen Y, Lee SM, Casing P, Bender
JG (2001) Differential effects of autologous serum on CD34+
or monocyte-derived dendritic cells. J Hematother Stem Cell
Res 10: 569-578
[15] Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R,
Burg G, Schadendorf D (1998) Vaccination of melanoma pa-
tients with peptide- or tumor lysate-pulsed dendritic cells. Nat
Med 4: 328-332
[16] Pietschmann P, Stockl J, Draxler S, Majdic O, Knapp W (2000)
Functional and phenotypic characteristics of dendritic cells
generated in human plasma supplemented medium. Scand J
Immunol 51: 377-383
[17] Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trocken-
bacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G
(1994) Proliferating dendritic cell progenitors in human blood.
J Exp Med 180: 83-93
[18] Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B,
Niederwieser D, Schuler G (1996) Generation of mature den-
dritic cells from human blood - an improved method with special
regard to clinical applicability. J Immunol Methods 196: 137-151
[19] Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N
(1997) A monocyte conditioned medium is more effective than
defined cytokines in mediating the terminal maturation of
human dendritic cells. Blood 90: 3640-3646
[20] Sallusto F, Lanzavecchia A (1994) Efficient presentation of
soluble antigen by cultured human dendritic cells is maintained
by granulocyte-macrophage colony-stimulating factor plus in-
terleukin 4 and downregulated by tumor necrosis factor α . J Exp
Med 179: 1109-1118
[21] Satthaporn S, Eremin O (2001) Dendritic cells (I): biological
function. J R Coll Surg Edinb 46: 9-20
[22] Steinmann RM, Pope M (2002) Exploiting dendritic cells to
improve vaccine efficacy. J Clin Invest 109: 1519-1526
[23] Sugita M, van Der Wel N, Rogers RA, Peters PJ, Brenner MB
(2000) CD1c molecules broadly survey the endocytic system.
Proc Natl Acad Sci USA 18: 8445-8450
[24] Syme R, Gluck S (2001) Effects on the culture and differentia-
tion of dendritic cells in vitro. J Hematother Stem Cell Res 10:
43-51
[25] Tarte K, Fiol G, Rossi JF, Klein B (2000) Extensive charac-
terization of dendritic cells generated in serum-free conditions:
regulation of soluble antigen uptake, apoptotic tumor cell pha-
gocytosis, chemotaxis and T cell activation during maturation
in vitro. Leukemia 14: 2182-2192
[26] Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser
A, Keikavoussi P, Kampgen E, Bender A, Schuler G (1999)
Generation of large numbers of fully mature and stable dendritic
cells from leukapheresis products for clinical application. J
Immunol Methods 223: 1-15
[27] de Vries IJ, Eggert AA, Scharenborg NM, Vissers JL, Lesterhuis
WJ, Boerman OC, Punt CJ, Adema GJ, Figdor CG (2002)
Phenotypical and functional characterization of clinical grade
dendritic cells. J Immunother 25: 429-439
[28] Wojas K, Tabarkiewicz J, Rolinski J (2003) Dendritic cells in
cancer immunotherapy - a short review. Folia Morphol 62:
317-318
Human dendritic cells in culture 29[29] Wurtzen PA, Nissen MH, Claesson MH (2001) Maturation of
dendritic cells by recombinant human CD40L-trimer leads to a
homogeneous cell population with enhanced surface marker
expression and increased cytokine production. Scand J Immu-
nol 53: 579-587
[30] Zheng Z, Takahashi M, Narita M, Toba K, Liu A, Furukawa T,
Koike T, Aizawa Y (2000) Generation of dendritic cells from
adherent cells of cord blood by culture with granulocyte-mac-
rophage colony-stimulating factor, interleukin-4, and tumor
necrosis factor-alpha. J Hematother Stem Cell Res 9: 453-464
[31] Zhou L, Tedder TF (1995) Human blood dendritic cells selec-
tively express CD83, a member of the immunoglobulin super-
family. J Immunol 154: 3821-3835
[32] Zhou L, Tedder TF (1996) CD14+ blood monocytes can dif-
ferentiate into functionally mature CD83+ dendritic cells. Proc
Natl Acad Sci USA 93: 2588-2592
Received April 13, 2004
       Accepted after revision July 30, 2004
30 N. Tkachenko et al.